医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Medical PDQ App is the Best Platform for COVID-19 Communication for Healthcare Providers and Patients

2020年03月13日 AM11:17
このエントリーをはてなブックマークに追加


 

FORT WORTH, Texas

With the uncontrollable global spread of the COVID-19 virus and quarantine orders from governments around the world, communication for healthcare providers and patients is becoming more challenging day after day. Agile Surgical Assistants, LLC believes Medical PDQ is the best mobile app platform for doctors and patients to connect without having to expose themselves to the coronavirus.

Fears of contracting and exposure of the COVID-19 virus, impacts the communication in the health industry for appointments and proper treatment for patients. Quarantine orders make it difficult for patients to schedule appointments while hospitals and clinics around the world are overwhelmed with an alarming rate of new cases everyday.

There is no cure or vaccine for COVID-19 but to aid in preventing the spread, communication is key. Medical PDQ provides a platform for communication amongst healthcare providers and patients for this type of outbreak. Healthcare providers can schedule patient’s appointments thru Medical PDQ, as well as direct message for consults, etc.

To aid in combatting and prevent the spread, Medical PDQ’s platform helps healthcare providers and their staff with clinic/surgery appointments, consults, emergencies, rescheduling and coverage requests, in real time. In matters of the pandemic spread of COVID-19, like any emergency, time is of the essence.

Start safely communicating (Android or iPhone) with your healthcare providers with MedicalPDQ.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200312005901/en/

CONTACT

Medical PDQ

Agile Surgical Assistants, LLC

Jacqueline Grant

CMO

contactus@medicalpdq.com

+1-888-637-3724 Ext 703

http://www.medicalpdq.com/

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • AriBio Co., Ltd. to Present Biomarker Data for AR1001 from the Mild to Moderate Alzheimer’s Disease Phase 2 Study at the International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD™ 2023)
  • サーモフィッシャーサイエンティフィックとアーセナル・バイオサイエンシズが自家T細胞治療薬の臨床製造支援で協業
  • 武田宣布将在即将召开的股东大会上公布董事会候选人
  • Joe Kiani荣获2023年Robert L. Wears患者安全领导奖
  • ユーサウンドとパートナーが次世代の市販用補聴器を提供へ